From: bliss@mouse-potato.com

Hi Typers and Readers,

Well you know what pharmeceutical companies are for,
making money!

Ketamine, one of the few drugs I have never sampled, turns
out to be a useful drug but it is out of protection so they
fiddled around so that now you will have to pay more for it.

Some researchers consequently question the need for next-generation drugs such as esketamine. “It's not going to do anything ketamine doesn't do, but it will cost 10 to 100 times as much as ketamine,” says Scott Thompson, a neurobiologist at the

University of Maryland. “If esketamine is safe enough to release into the general population, then ketamine is safe enough. It's a backwards way to get a
drug approved.”

Read the rest of the story at:

<https://www.scientificamerican.com/article/party-drug-turned-antidepressant-approaches-approval/>

bliss

--
bliss dash SF 4 ever at dslextreme dot com

--- SoupGate-Win32 v1.05
* Origin: www.darkrealms.ca (1:229/2)

From: joelcrump@gmail.com

On 2/26/19 8:37 PM, Bobbie Sellers wrote:

Hi Typers and Readers,

    Well you know what pharmeceutical companies are for,
making money!

    Ketamine, one of the few drugs I have never sampled, turns
out to be a useful drug but it is out of protection so they
fiddled around so that now you will have to pay more for it.

Some researchers consequently question the need for next-generation
drugs such as esketamine. “It's not going to do anything ketamine
doesn't do, but it will cost 10 to 100 times as much as ketamine,”
says Scott Thompson, a neurobiologist at the University of Maryland.
“If esketamine is safe enough to release into the general population,
then ketamine is safe enough. It's a backwards way to get a drug
approved.”

    Read the rest of the story at:

<https://www.scientificamerican.com/article/party-drug-turned-antidepressant-approaches-approval/>

Interesting, thanks!

--
Joel Crump

--- SoupGate-Win32 v1.05
* Origin: www.darkrealms.ca (1:229/2)